NO995036L - 5,7-disubstituerte 4-aminopyrido[2,3-d]pyrimidinforbindelser og deres anvendelse som adenosinkinaseinhibitorer - Google Patents
5,7-disubstituerte 4-aminopyrido[2,3-d]pyrimidinforbindelser og deres anvendelse som adenosinkinaseinhibitorerInfo
- Publication number
- NO995036L NO995036L NO995036A NO995036A NO995036L NO 995036 L NO995036 L NO 995036L NO 995036 A NO995036 A NO 995036A NO 995036 A NO995036 A NO 995036A NO 995036 L NO995036 L NO 995036L
- Authority
- NO
- Norway
- Prior art keywords
- heterocyclyl
- heteroaryl
- aryl
- compound
- lower alkyl
- Prior art date
Links
- -1 5,7-Disubstituted 4-Aminopyrido [2,3-d] Pyrimidine Compounds Chemical class 0.000 title 1
- 239000003121 adenosine kinase inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 5
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 241000124008 Mammalia Species 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- OOXNYFKPOPJIOT-UHFFFAOYSA-N 5-(3-bromophenyl)-7-(6-morpholin-4-ylpyridin-3-yl)pyrido[2,3-d]pyrimidin-4-amine;dihydrochloride Chemical compound Cl.Cl.C=12C(N)=NC=NC2=NC(C=2C=NC(=CC=2)N2CCOCC2)=CC=1C1=CC=CC(Br)=C1 OOXNYFKPOPJIOT-UHFFFAOYSA-N 0.000 abstract 1
- 108010076278 Adenosine kinase Proteins 0.000 abstract 1
- 102100032534 Adenosine kinase Human genes 0.000 abstract 1
- 201000006474 Brain Ischemia Diseases 0.000 abstract 1
- 206010008120 Cerebral ischaemia Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010040047 Sepsis Diseases 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 206010008118 cerebral infarction Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000020341 sensory perception of pain Effects 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83821697A | 1997-04-16 | 1997-04-16 | |
| PCT/US1998/007207 WO1998046605A1 (fr) | 1997-04-16 | 1998-04-14 | Composes de 4-aminopyrido[2,3-d]pyrimidine 5,7-disubstitues et leur utilisation comme inhibiteurs de l'adenosine kinase |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO995036L true NO995036L (no) | 1999-10-15 |
| NO995036D0 NO995036D0 (no) | 1999-10-15 |
Family
ID=25276561
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO995036A NO995036D0 (no) | 1997-04-16 | 1999-10-15 | 5,7-disubstituerte 4-aminopyrido[2,3-d]pyrimidinforbindelser og deres anvendelse som adenosinkinaseinhibitorer |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP0989986A1 (fr) |
| JP (1) | JP2001520655A (fr) |
| KR (1) | KR20010006509A (fr) |
| CN (1) | CN1252070A (fr) |
| AR (1) | AR012436A1 (fr) |
| AU (1) | AU7108398A (fr) |
| BG (1) | BG103842A (fr) |
| BR (1) | BR9809055A (fr) |
| CA (1) | CA2286909A1 (fr) |
| CO (1) | CO4940446A1 (fr) |
| HU (1) | HUP0001434A3 (fr) |
| IL (1) | IL131618A0 (fr) |
| NO (1) | NO995036D0 (fr) |
| PL (1) | PL336304A1 (fr) |
| SK (1) | SK141799A3 (fr) |
| TR (1) | TR199902455T2 (fr) |
| WO (1) | WO1998046605A1 (fr) |
| ZA (1) | ZA983177B (fr) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000023444A1 (fr) * | 1998-10-21 | 2000-04-27 | Abbott Laboratories | Composes de 4-aminopyrido[2,3-d]pyrimidine a disubstitution 5,7 |
| AU2002256615B2 (en) | 2001-02-12 | 2007-09-13 | F. Hoffmann-La Roche Ag | 6-substituted pyrido-pyrimidines |
| PL371587A1 (en) | 2002-01-17 | 2005-06-27 | Neurogen Corporation | Substituted quinazolin-4-ylamine analogues as modulators of capsaicin receptors |
| DE10335183A1 (de) * | 2003-07-30 | 2005-02-24 | Bayer Cropscience Ag | Fungizide Wirkstoffkombinationen |
| ATE449097T1 (de) * | 2005-07-21 | 2009-12-15 | Hoffmann La Roche | Pyridoä2,3-düpyrimidin-2,4-diamin-verbindungen als ptpib-hemmer |
| RU2441869C2 (ru) * | 2005-12-21 | 2012-02-10 | Эбботт Лэборетриз | Противовирусные соединения |
| WO2007081517A2 (fr) | 2005-12-21 | 2007-07-19 | Abbott Laboratories | Composes anti-viraux |
| WO2008133753A2 (fr) | 2006-12-20 | 2008-11-06 | Abbott Laboratories | Composés antiviraux |
| JP5718053B2 (ja) | 2007-08-27 | 2015-05-13 | ヘリコン・セラピューティクス・インコーポレーテッド | 治療用イソオキサゾール化合物 |
| CN101815713B (zh) | 2007-08-31 | 2013-09-11 | 卫材R&D管理有限公司 | 多环化合物 |
| DE102007061764A1 (de) * | 2007-12-20 | 2009-06-25 | Bayer Healthcare Ag | Anellierte Cyanopyridine und ihre Verwendung |
| RU2515976C2 (ru) * | 2009-02-26 | 2014-05-20 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Азотсодержащие конденсированные гетероциклические соединения и их применение в качестве ингибиторов продукции бета-амилоида |
| WO2014055595A1 (fr) | 2012-10-05 | 2014-04-10 | Merck Sharp & Dohme Corp. | Composés d'indoline utilisés comme inhibiteurs de l'aldostérone synthase et applications s'y rapportant |
| JP6864379B2 (ja) | 2016-03-31 | 2021-04-28 | オンターナル セラピューティック インコーポレイテッドＯｎｃｔｅｒｎａｌ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | インドール類似体及びその使用 |
| CN110256420B (zh) * | 2019-05-07 | 2020-04-28 | 江西中医药大学 | 四氢吡啶并嘧啶衍生物及其制备方法和用途 |
| CN110283171A (zh) * | 2019-07-17 | 2019-09-27 | 鼎泰(南京)临床医学研究有限公司 | 一类含有吡啶并嘧啶-4-胺类结构的化合物、药物组合物以及其应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5324731A (en) * | 1989-02-14 | 1994-06-28 | Amira, Inc. | Method of inhibiting transformation of cells in which purine metabolic enzyme activity is elevated |
| IL112249A (en) * | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| US6143749A (en) * | 1995-06-07 | 2000-11-07 | Abbott Laboratories | Heterocyclic substituted cyclopentane compounds |
-
1998
- 1998-04-14 SK SK1417-99A patent/SK141799A3/sk unknown
- 1998-04-14 HU HU0001434A patent/HUP0001434A3/hu unknown
- 1998-04-14 IL IL13161898A patent/IL131618A0/xx unknown
- 1998-04-14 WO PCT/US1998/007207 patent/WO1998046605A1/fr not_active Ceased
- 1998-04-14 PL PL98336304A patent/PL336304A1/xx unknown
- 1998-04-14 TR TR1999/02455T patent/TR199902455T2/xx unknown
- 1998-04-14 CA CA002286909A patent/CA2286909A1/fr not_active Abandoned
- 1998-04-14 AU AU71083/98A patent/AU7108398A/en not_active Abandoned
- 1998-04-14 KR KR1019997009599A patent/KR20010006509A/ko not_active Withdrawn
- 1998-04-14 CN CN98804151A patent/CN1252070A/zh active Pending
- 1998-04-14 JP JP54408898A patent/JP2001520655A/ja active Pending
- 1998-04-14 BR BR9809055-0A patent/BR9809055A/pt not_active Application Discontinuation
- 1998-04-14 EP EP98918093A patent/EP0989986A1/fr not_active Withdrawn
- 1998-04-15 ZA ZA983177A patent/ZA983177B/xx unknown
- 1998-04-15 AR ARP980101733A patent/AR012436A1/es unknown
- 1998-04-16 CO CO98020979A patent/CO4940446A1/es unknown
-
1999
- 1999-10-15 NO NO995036A patent/NO995036D0/no not_active Application Discontinuation
- 1999-10-29 BG BG103842A patent/BG103842A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR012436A1 (es) | 2000-10-18 |
| IL131618A0 (en) | 2001-01-28 |
| HUP0001434A2 (hu) | 2000-10-28 |
| CN1252070A (zh) | 2000-05-03 |
| TR199902455T2 (xx) | 2000-01-21 |
| CA2286909A1 (fr) | 1998-10-22 |
| CO4940446A1 (es) | 2000-07-24 |
| BG103842A (bg) | 2000-06-30 |
| KR20010006509A (ko) | 2001-01-26 |
| JP2001520655A (ja) | 2001-10-30 |
| ZA983177B (en) | 1999-01-22 |
| PL336304A1 (en) | 2000-06-19 |
| SK141799A3 (en) | 2000-08-14 |
| EP0989986A1 (fr) | 2000-04-05 |
| AU7108398A (en) | 1998-11-11 |
| HUP0001434A3 (en) | 2001-01-29 |
| WO1998046605A1 (fr) | 1998-10-22 |
| BR9809055A (pt) | 2000-08-08 |
| NO995036D0 (no) | 1999-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO995036L (no) | 5,7-disubstituerte 4-aminopyrido[2,3-d]pyrimidinforbindelser og deres anvendelse som adenosinkinaseinhibitorer | |
| JP6524081B2 (ja) | ジヒドロピリミジン化合物及び医薬におけるその適用 | |
| EP3122747B1 (fr) | Composés dihydropyrimidine et leur application dans des produits pharmaceutiques | |
| CA2927373C (fr) | Procedes de preparation de derives de dihydropyrimidine, et intermediaires de ceux-ci | |
| KR102821964B1 (ko) | 치환된 피롤로피리미딘 jak 억제제 및 이의 제조 및 사용 방법 | |
| HUP0100348A2 (hu) | Hattagú, egy vagy két nitrogénatomot tartalmazó kondenzál biciklusok, eljárás előállításukra, alkalmazásuk, a vegyületeket tartalmazó gyógyszerkészítmények, valamint intermedierek | |
| AR063351A1 (es) | DERIVADOS DE PURINA Y DE PIRIMIDINAS CONDENSADAS, COMPOSICION Y SU USO EN LA PREPARACIoN DE UN MEDICAMENTO PARA INHIBIR EL HSP90 EN UNA CELULA. | |
| NO20072115L (no) | Farmasoytiske forbindelser | |
| EP2597087A1 (fr) | Dérivés dihydrooxazine et tétrahydropyrimidine comme inhibiteurs de BACE 1 | |
| NO331068B1 (no) | Benzazepinderivater for behandling av nevrologiske forstyrrelser. | |
| KR20090079257A (ko) | 치환된 3-이소부틸-9,10-디메톡시-1,3,4,6,7,11ｂ-헥사히드로-2Ｈ-피리도[2,1-ａ]이소퀴놀린-2-올 화합물 및 그와 관련된 방법 | |
| KR20220041180A (ko) | 중소수화 mk2 경로 억제제 및 이를 이용하는 방법 | |
| CA2942599A1 (fr) | Amides n-[2-(2-amino-6,6-disubstitues-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8h)-yl)-1,3-thiazol-4-yl] | |
| WO2021022178A1 (fr) | Pyrrolopyridines de sulfonamide substituées servant d'inhibiteurs de jak | |
| WO2023160572A1 (fr) | Dérivé de pyrazole, composition pharmaceutique et utilisation | |
| CA2042113A1 (fr) | Spiro-isoquinoleinepyrrolidine et leurs analogues, utiles comme agents inhibiteurs de l'aldose-reductase | |
| NO179974C (no) | Analogifremgangsmåte for fremstilling av terapeutisk aktive piperidinforbindelser | |
| NO20060650L (no) | Kinazolinderivater som angiogeneseinhibitorer | |
| RU97115107A (ru) | Бициклические производные изотиомочевины, применяемые в терапии | |
| CO5540385A2 (es) | Derivados quirales de acido oxazol arilpropionico, su metodo de sintesis ycomposiciones farmaceuticas que los contienen | |
| SK164397A3 (en) | Method for preparing n-monosubstituted and n,n'-disubstituted unsymmetrical cyclic ureas | |
| ES2918186T3 (es) | Pirazolopirimidinas que tienen actividad contra el virus sincitial respiratorio (VSR) | |
| IL95250A (en) | 1-(pyridinylamino)-2-pyrrolidinones, a process for their preparation and their use as medicaments | |
| TW202315869A (zh) | 亞磺醯亞胺類化合物及其應用 | |
| ES3013859T3 (en) | Mdm2 inhibitor, preparation method therefor, pharmaceutical composition thereof, and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |